---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061130"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:57:32.016547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024

## Summary
- Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.
- Cash position $268.6M; expects 2024 operating cash burn below $200M, runway into 2025.
- Phase 1 ARDENT trial for SC291 (CD19-directed CAR T) enrolling; initial data expected 2023, more robust in 2024.
- CTA submitted for IST of HIP-modified primary islet cells in type 1 diabetes; data expected 2023 and 2024.
- IND submitted for SC291 in B-cell autoimmune diseases; SC262 IND on track for 4Q 2023; data expected 2024.

## SEC filing metadata
- accession: 0000950170-23-061130
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/0000950170-23-061130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/sana-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061130
- JSON: https://secwatch.observer/filing/0000950170-23-061130.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061130.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On November 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/0000950170-23-061130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.